{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
"ANANDAMIDE"
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
(R)- enantiomer does not exhibit COX inhibition – it was > 100-fold less active than (S)- enantiomer on both COX subtypes. (R)- enantiomer is about 60 times less potent than the (-)-S isomer in the carrageenan edema test and ca. 230 times less active than the (-)-S isomer in the mouse phenylquinone writhing assay. R-ketorolac is an inhibitor of fatty acid amide hydrolase, but not at physiological concentrations.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
PF-3845 is a selective covalent inhibitor of fatty acid amide hydrolase. It results in increased levels of anandamide and results in cannabinoid receptor-based effects. PF-3845 demonstrated cannabinoid receptor-dependent antinociceptive effects in models of inflammatory and neuropathic pain. In mouse model PF-3845 attenuated withdrawal from morphine dependence. PF3845 reversed traumatic brain injury (TBI)-induced impairments in fine motor movement, hippocampus dependent working memory and anxiety-like behavior in a tramatic brain injury model.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
JNJ-1661010 is a potent and selective is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. FAAH is a membrane bound serine hydrolase primarily responsible for the breakdown of the endogenous cannabinoid anandamide in the CNS. Increasing the amount of anandamide, which has analgesics properties, may be efficacious in the treatment of pain. According to the experimental data JNJ-1661010 may be useful clinically as broad-spectrum analgesics. Johnson & Johnson is developing JNJ-1661010 for the treatment of neuropathic pain. Preclinical development is being conducted in the US. In addition recent data demonstrated that JNJ-1661010 could be useful in the treatment of arthritis and parkinson's disease. JNJ-1661010 inhibits myometrial contractility, without un-specific relaxing effects on the smooth muscle.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
PF-750 is a covalent irreversible inhibitor of FAAH, discovered by Pfizer.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Tribufos is an organophosphate defoliant used for cotton crops. It is specifically used to defoliate cotton in preparation for machine harvesting. Tribufos inhibits CB1 in vivo, without cholinergic poisoning signs, by 50% at 50 mg/kg intraperitoneally with a recovery half-time of 3-4 days, indicating covalent derivatization.
